Morristown, NJ, November 11, 2011 - Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Morphine Sulfate Extended-Release Capsules, USP CII, an authorized generic of KADIAN^®.

Actavis has been manufacturing KADIAN^® for 15 years and has in-depth expertise in the development and manufacturing of complex controlled-release pharmaceuticals. 

Kadian^® US sales have grown 50% in the last 5 years to approximately $275 million for the 12 months ending September 30, 2011, according to IMS Health.

For prescribing information, please download MorphineSulfateExtendedReleaseCapsulesUSPGenericofKadian.pdf(135KB)